Hepatitis Testing Market Projected to Reach USD 5.75 Billion by 2032, Expanding at a CAGR of 5.62%

The global hepatitis testing market is fueled by rapid diagnostics, POC testing, and public health initiatives targeting prevention and treatment.



Hepatitis Testing Market

AUSTIN, TX, UNITED STATES, February 12, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The Hepatitis Testing Market size was estimated at USD 3.53 billion in 2023 and is expected to reach USD 5.75 billion by 2032 at a CAGR of 5.62% during the forecast period of 2024-2032.

The rising hepatitis burden, with 254 million living with hepatitis B and 50 million with hepatitis C globally by 2022, underscores the need for improved testing solutions. Hepatitis has become the second leading cause of death from communicable diseases after COVID-19, with 1.3 million deaths in 2022. Improving rapid diagnostics and proactive governance will prevent millions of infections, save USD 99 billion by 2050, and spur strong growth in the hepatitis testing market.

> Advancements in hepatitis testing, such as rapid diagnostics and point-of-care solutions, are essential to improving early detection and expanding access to life-saving treatments worldwide.”
>
> *SNS Insider*

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/4692

By Test: The imaging tests segment projected the fastest growth is around 6.49% during the forecast period from 2024 to 2032.

The reason for the fastest growth of the imaging tests segment is that AI-driven analysis and non-invasive imaging techniques improve accuracy and sensitivity. Advances in these aspects make imaging tests an ideal painless, precise monitoring solution and hold significant potential to complement other diagnostic methods present in the hepatitis testing market. In 2023, the blood tests segment dominated the hepatitis testing market with around 54% of the market share. Blood tests were close to diagnosing over 70% of hepatitis worldwide in 2022 because they are effective in early detection and management of the disease. In addition, they are relatively cost-effective and easily accessible for mass screening.

By product: The Instruments segment Projected the Fastest Growth

The instruments segment is expected to achieve the highest CAGR of approximately 6.24% between 2024 and 2032, driven by ongoing technological advancements that improve the precision and speed of hepatitis testing. The rising demand for reliable diagnostic solutions is fueling growth in both reagents and instruments, which are pivotal for enhancing healthcare testing capabilities. These innovations are likely to be of prime importance in advancing early detection and treatment strategies for hepatitis infections, thus supporting significant market expansion. Growth in this direction is further supported by increased investments in healthcare infrastructure worldwide.

By technology: The rapid diagnostic tests segment is poised to become the fastest-growing segment, with an expected CAGR from 2024 to 2032 of 7.29%.

Because these tests are quick, cost-effective, and easy to use, thereby suitable for resource-limited settings. RDTs provide a result within 15-30 minutes without needing specialized laboratory equipment or trained personnel. These include immunoassays and molecular tests, thus facilitating early diagnosis and timely treatment, which are important for hepatitis management. The rising incidence of hepatitis, as well as the need for user-friendly and highly reliable diagnostic methods, has popularized the widespread use of RDTs in low- and middle-income countries.

By end user: The blood banks segment leads the fastest growth; hospitals and diagnostic laboratories segment still dominate

Hospitals and diagnostic laboratories segment were the market leaders in hepatitis testing in 2023, accounting for 63% of the total market share. They are well-equipped with modern technologies that help in accurate and efficient diagnosis. Their wide-ranging testing capabilities ensure timely results, thus allowing timely treatment and proper management of patients infected with hepatitis. Being central points for healthcare services, they remain the first preference for hepatitis testing, thus making them the market leaders.

Regional Analysis: In 2023, North America dominated the market with 43% of the hepatitis testing market

Because of its established healthcare infrastructure, high healthcare spending, and increased adoption of sophisticated diagnostic technologies. The region is characterized by sound healthcare systems, strong government support for health initiatives, and the high prevalence of chronic diseases, which drives demand for quick and accurate diagnostic solutions. Moreover, the presence of leading diagnostic companies and regulatory approvals in North America significantly contributes to its market leadership.

Asia Pacific projected the fastest growth throughout the forecast period. Awareness for the infectious disease rises and grows higher, hence boosting demand in emergent economies and accessible low-cost diagnostic solutions for them. With the increasing populace, higher incidents of chronic, infectious diseases with the efforts being taken to the government of countries for developing infrastructures. Adoption of RDTs in rural and underserved areas, where traditional lab-based testing is limited, is also contributing to the growth of the market.

Need any customization research on Hepatitis Testing Market, Enquire Now@
https://www.snsinsider.com/enquiry/4692

Key Players in Hepatitis Testing Market
- Abbott Laboratories (Architect Anti-HCV, Alinity HCV)
- Analytik Jena (AdiSelect HCV, AdiSelect HCV Real-Time PCR Kit)
- Autobio Diagnostics (HCV Antibody Test Kit, HEV Antibody Test Kit
- Bio-Mérieux (VIDAS Anti-HCV, VIDAS HEV)
- Danaher Corporation (Cepheid Xpert HCV, LumiraDx HCV Test)
- DiaSorin (LIAISON HCV, LIAISON HCV)
- Grifols SA (Procleix HCV Assay, Procleix HEV Assay)
- Hologic Inc. (Aptima HCV Assay, Aptima HEV Assay)
- MedMira Inc. (Reveal HCV Test, Reveal HEV Test)
- Ortho-Clinical Diagnostics (Vitros Anti-HCV Test, Vitros HEV Test)
- Qualpro Diagnostics (HCV Rapid Test, HEV Rapid Test)
- Roche Molecular Diagnostics(Cobas HCV Test, Cobas HEV Test
- Siemens Healthcare(ADVIA Centaur HCV , Dimension Vista HEV)
- Sysmex Corporation(Sysmex HCV Test, Sysmex HCV Test)
- Thermo Fisher Scientific(TaqMan HCV Test, HCV Viral Load Test)
- PerkinElmer (HCV Viral Load Test, HEV Serology Test)
- Qiagen (QIAstat-Dx Respiratory Panel, QIAamp Viral RNA Mini Kit)
- Becton, Dickinson and Company (BD) (BD MAX HCV Test, BD Veritor System for HCV)
- Myriad Genetics (Myriad RBM HCV Antibody Test, F. Hoffmann-La Roche LtD

Table of Contents – Major Key Points

7. Hepatitis Testing Market by Test
8. Hepatitis Testing Market by Technology
9. Hepatitis Testing Market by End Use
10. Hepatitis Testing Market by Product
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion

Buy Full Research Report on Hepatitis Testing Market 2024-2032 @ https://www.snsinsider.com/checkout/4692

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
